A proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-control, nonatopic asthma
G Garcia, A Magnan, R Chiron, C Contin-Bordes… - Chest, 2013 - Elsevier
Background While up to 50% of patients with severe asthma have no evidence of allergy,
IgE has been linked to asthma, irrespective of atopic status. Omalizumab, an anti-IgE …
IgE has been linked to asthma, irrespective of atopic status. Omalizumab, an anti-IgE …
'Real‐life'effectiveness studies of omalizumab in adult patients with severe allergic asthma: systematic review
I Abraham, A Alhossan, CS Lee, H Kutbi… - Allergy, 2016 - Wiley Online Library
Abstract We reviewed 24 'real‐life'effectiveness studies of omalizumab in the treatment of
severe allergic asthma that included 4117 unique patients from 32 countries with significant …
severe allergic asthma that included 4117 unique patients from 32 countries with significant …
Omalizumab: an update on efficacy and safety in moderate-to-severe allergic asthma.
BE Chipps, M Figliomeni… - Allergy & Asthma …, 2012 - search.ebscohost.com
Omalizumab is an anti-immunoglobulin E (anti-IgE) monoclonal antibody approved in the
United States since 2003 for treatment of moderate-to-severe allergic asthma in adults and …
United States since 2003 for treatment of moderate-to-severe allergic asthma in adults and …